Capstone Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Capstone Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,072	Closed	-$37K	–	1693
2014 Q1	$37K	Hold	3,072	–	–	﹤0.01%	1739
2013 Q4	$39K	Sell	3,072 -312	-9%	-$4.96K	﹤0.01%	1857
2013 Q3	$56K	Hold	3,384	–	–	﹤0.01%	1981
2013 Q2	$51K	Buy	+3,384	New	+$51.4K	﹤0.01%	1931

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capstone Asset Management's LXRX Position: Q2 2014 in Review

Capstone Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2014, closing a stake of 3,072 shares — an estimated $37K sold.

Capstone Asset Management first reported a position in LXRX in Q2 2013 and held it in 4 quarters. The position peaked at $56K in Q3 2013. 99 funds tracked by Wall St. Rank hold LXRX as of Q2 2014.

Capstone Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Capstone Asset Management sold 3,072 Lexicon Pharmaceuticals shares in Q2 2014, an estimated $37K.
Capstone Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Capstone Asset Management's Lexicon Pharmaceuticals position peaked at $56K in Q3 2013.
99 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2014.

Based on Capstone Asset Management's 13F filing for Q2 2014, filed 11 Jul 2014.